Vorsoritide ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
276Achondroplasia2

276. Achondroplasia


Clinical trials : 46 Drugs : 29 - (DrugBank : 6) / Drug target genes : 5 - Drug target pathways : 30
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-000701-21-DE
(EUCTR)
19/06/201727/04/2017A study looking at growth measurements of children with achondroplasiaA Multicenter, Multinational Clinical Assessment Study for PediatricPatients with Achondroplasia Achondroplasia
MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
INN or Proposed INN: vorsoritideBioMarin Pharmaceutical Inc.NULLNot RecruitingFemale: yes
Male: yes
500Phase 1France;United States;Spain;Turkey;Australia;Germany;United Kingdom;Japan
2EUCTR2015-003836-11-ES
(EUCTR)
19/04/201710/03/2017A Phase 3 Study to Evaluate the Safety and Efficacy of BMN 111 in Children with AchondroplasiaA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia. - achondroplasia
MedDRA version: 19.1;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Product Name: modified recombinant human C-type natriuretic peptide
Product Code: BMN 111
INN or Proposed INN: vorsoritide
Other descriptive name: MODIFIED RHCNP
BioMarin Pharmaceutical Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 3France;United States;Spain;Turkey;Australia;Germany;Japan;United Kingdom